Abstract
Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.
Original language | English |
---|---|
Pages (from-to) | 1339-1346 |
Number of pages | 8 |
Journal | Neural Regeneration Research |
Volume | 11 |
Issue number | 8 |
DOIs | |
Publication status | Published - 1 Aug 2016 |
Keywords
- Bis(propyl)-cognitin
- Dopamine
- Monoamine oxidase B
- Multitarget
- Nerve regeneration
- Neural regeneration
- Neuroprotection
- Parkinson’s disease
- Rasagiline
- Synergism
ASJC Scopus subject areas
- Developmental Neuroscience